Sugi Predict

Sugi Predict / Targets / RIPK2

RIPK2

Receptor-interacting serine/threonine-protein kinase 2 · O43353 · RIPK2 on Sugi Atlas →

112,489 patent compounds predicted against RIPK2, 86,142 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL188755 SCHEMBL188755 0.76 10/20
Pd-0166285 Pd-0166285 (SCHEMBL133914) 1.00 8/20
SCHEMBL173288 SCHEMBL173288 1.00 4/20
SCHEMBL115598 SCHEMBL115598 0.39 4/20
Pd-169316 Pd-169316 (SCHEMBL154958) 1.00 3/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.67 3/20
Sb-203580 Sb-203580 (SCHEMBL146399) 0.67 3/20
SCHEMBL178158 SCHEMBL178158 0.63 3/20
SCHEMBL189162 SCHEMBL189162 0.55 3/20
SCHEMBL188862 SCHEMBL188862 0.53 3/20
SCHEMBL171273 SCHEMBL171273 0.53 3/20
SCHEMBL129858 SCHEMBL129858 0.50 3/20
SCHEMBL171216 SCHEMBL171216 0.50 3/20
SCHEMBL171196 SCHEMBL171196 0.48 3/20
SCHEMBL156688 SCHEMBL156688 0.42 3/20
SCHEMBL181762 SCHEMBL181762 0.41 3/20
SCHEMBL126869 SCHEMBL126869 0.41 3/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 2/20
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 2/20
Tivozanib Tivozanib (SCHEMBL172883) 1.00 2/20

Clinical trials — most relevant to RIPK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Cardiotoxicity in Breast Cancer Patients PHASE4RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Clinical and Genomic Responses to Open Heart Surgery PHASE3COMPLETED
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus PHASE2/PHASE3UNKNOWN
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response PHASE2UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study PHASE2COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia EARLY_PHASE1COMPLETED
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Remote Ischemic Preconditioning to Prevent Contrast-Induced Kidney Injury in Diabetic Patients (PRINCES) nanCOMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RIPK2 binder may also engage these)

ProteinNameSimilarity
P58801 — 1.000 P58801 →
Q3SZJ2 — 0.996 Q3SZJ2 →
Q8K4B2 — 0.981 Q8K4B2 →
P38438 — 0.965 P38438 →
TGFBR2 TGF-beta receptor type-2 0.965 landscape →
Q62312 — 0.963 Q62312 →
IRAK3 Interleukin-1 receptor-associated kinase 3 0.961 landscape →
Q90999 — 0.958 Q90999 →
O15519 — 0.953 O15519 →
Q3UGM2 — 0.952 Q3UGM2 →
Q5RD56 — 0.952 Q5RD56 →
P34925 — 0.949 P34925 →
Q9ESL4 — 0.949 Q9ESL4 →
Q01887 — 0.948 Q01887 →
Q5REY7 — 0.948 Q5REY7 →
O94888 — 0.948 O94888 →
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 0.947 landscape →
Q9Z1S3 — 0.947 Q9Z1S3 →
Q8C0Q9 — 0.946 Q8C0Q9 →
Q90669 — 0.946 Q90669 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.946 landscape →
Q2TBA3 — 0.945 Q2TBA3 →
G3X9X1 — 0.944 G3X9X1 →
Q5JSP0 — 0.944 Q5JSP0 →
Q9CWU0 — 0.943 Q9CWU0 →
RASGRP1 RAS guanyl-releasing protein 1 0.943 landscape →
P33497 — 0.943 P33497 →
Q3LAC4 — 0.943 Q3LAC4 →
Q7TQP6 — 0.942 Q7TQP6 →
Q70Z35 — 0.942 Q70Z35 →